No connection

Search Results

ALHC vs LGND

ALHC
Alignment Healthcare, Inc.
BEARISH
Price
$19.22
Market Cap
$3.85B
Sector
Healthcare
AI Confidence
85%
LGND
Ligand Pharmaceuticals Incorporated
NEUTRAL
Price
$204.92
Market Cap
$4.09B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ALHC
--
LGND
33.43
Forward P/E
ALHC
26.79
LGND
20.7
P/B Ratio
ALHC
21.89
LGND
3.98
P/S Ratio
ALHC
0.97
LGND
15.24
EV/EBITDA
ALHC
80.67
LGND
46.98

Profitability

Gross Margin
ALHC
12.37%
LGND
64.29%
Operating Margin
ALHC
-1.01%
LGND
33.59%
Profit Margin
ALHC
-0.02%
LGND
46.42%
ROE
ALHC
-0.7%
LGND
13.47%
ROA
ALHC
1.0%
LGND
2.36%

Growth

Revenue Growth
ALHC
44.4%
LGND
39.4%
Earnings Growth
ALHC
--
LGND
--

Financial Health

Debt/Equity
ALHC
1.84
LGND
0.44
Current Ratio
ALHC
1.71
LGND
22.23
Quick Ratio
ALHC
1.54
LGND
21.83

Dividends

Dividend Yield
ALHC
--
LGND
--
Payout Ratio
ALHC
0.0%
LGND
0.0%

AI Verdict

ALHC BEARISH

ALHC's Advanced Deterministic Scorecard reveals significant financial health concerns, with a Piotroski F-Score of 2/9 indicating weak operational and financial stability. The absence of an Altman Z-Score and the company's high debt/equity ratio of 1.84 raise distress risk concerns, especially given negative profitability metrics and a lack of positive cash flow indicators. Despite strong revenue growth (44.4% YoY) and impressive earnings surprises in recent quarters, the company remains unprofitable with negative ROE (-0.70%) and ROA (1.00%), undermining long-term sustainability. Insider selling totaling $454.78M over six months signals strong bearish sentiment from leadership, further eroding confidence. The stock trades at a premium valuation (Price/Book: 21.89) despite poor profitability, suggesting overvaluation relative to fundamentals.

Strengths
Strong revenue growth of 44.4% YoY, indicating market expansion and execution capability
Exceptional earnings surprise history with average 458.81% beat in last 4 quarters
Positive recent EPS growth (Q/Q: +42.9%, YoY: +171.4%) signaling improving profitability trajectory
Risks
Piotroski F-Score of 2/9 indicates severe financial distress signals and weak operational efficiency
Negative ROE (-0.70%) and ROA (1.00%) reflect poor capital utilization and unprofitability
Debt/Equity ratio of 1.84 is high, especially for a loss-making company with no clear path to profitability
LGND NEUTRAL

LGND presents a dichotomy between exceptional operational profitability and poor deterministic health/value scores. While the company boasts a massive 46.42% profit margin and strong revenue growth (39.4%), the Piotroski F-Score of 3/9 indicates weak financial trend momentum. The stock is trading at a significant premium to its Graham Number ($84.23) and Intrinsic Value ($42.91), suggesting the market is pricing in aggressive future growth. Bearish insider activity and a weak technical trend further temper the outlook despite strong analyst target prices.

Strengths
Exceptional profit margins (46.42%) and gross margins (64.29%)
Strong top-line growth with 39.40% YoY revenue increase
Extremely high liquidity indicated by a Current Ratio of 22.23
Risks
Severe overvaluation relative to Graham and Intrinsic value benchmarks
Weak financial health trend as evidenced by a Piotroski F-Score of 3/9
Bearish insider sentiment with 9 sell transactions and 0 buys

Compare Another Pair

ALHC vs LGND: Head-to-Head Comparison

This page compares Alignment Healthcare, Inc. (ALHC) and Ligand Pharmaceuticals Incorporated (LGND) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile